SEARCH

SEARCH BY CITATION

References

  • 1
    Wong ND, Lopez VA, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med. 2007;167:24312436.
  • 2
    Hyre AD, Muntner P, Menke A, et al. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol. 2007;17:548555.
  • 3
    Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10:926932.
  • 4
    Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98:204208.
  • 5
    Erhardt LR. Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag. 2007;3:985997.
  • 6
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:24862497.
  • 7
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 8
    Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459467.
  • 9
    Allison TG, Squires RW, Johnson BD, et al. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc. 1999;74:466473.
  • 10
    Blank R, Hobbs FD, Zamorano J, et al. A single-pill combination of amlodipine besylate and atorvastatin calcium (update). Drugs Today (Barc). 2007;43:157177.
  • 11
    Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich). 2005;7:264273.
  • 12
    Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the GEMINI-AALA study). J Hum Hypertens. 2008; Sep 18 [Epub ahead of print].
  • 13
    Feldman R on behalf of the JEWEL Study Group. Multiple risk intervention with a single-pill combination (amlodipine/atorvastatin) helps patients to attain recommended target levels for blood pressure and lipids (The JEWEL Program). J Clin Hypertens. 2006;8:455.
  • 14
    Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83:3545.
  • 15
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720732.
  • 16
    National Cholesterol Education Program of the National Institutes of Health National Heart Lung and Blood Institute. Spreadsheet-Based 10-Year Risk Assessment Tool http://hin.nhlbi.nih.gov/atpiii/riskcalc.htm. Accessed December 17, 2008.
  • 17
    National Heart Lung, and Blood Institute. Cardiovascular Disease Risk Reduction, Adults Cholesterol Guidelines Update, ATP IV Hypertension Guidelines Update, JNC 8 Obesity Guidelines Update. 2008. http://www.nhlbi.nih.gov/guidelines/cvd_adult/background.htm. Accessed December 17, 2008.